[{"id":"89c75df9-9804-4899-a467-168d5893aeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316116","created_at":"2022-04-07T13:56:37.378Z","updated_at":"2025-02-25T17:01:47.416Z","phase":"Phase 1","brief_title":"Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)","source_id_and_acronym":"NCT05316116","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sylvant (siltuximab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 11/17/2026","primary_completion_date":" 11/17/2026","study_txt":" Completion: 11/17/2027","study_completion_date":" 11/17/2027","last_update_posted":"2025-02-03"},{"id":"8e68b197-bc4f-4479-9ecd-61cd7d26dc27","acronym":"MEPI-AGE","url":"https://clinicaltrials.gov/study/NCT06761274","created_at":"2025-02-26T07:31:58.859Z","updated_at":"2025-02-26T07:31:58.859Z","phase":"","brief_title":"Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma","source_id_and_acronym":"NCT06761274 - MEPI-AGE","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" KLRG1 • B3GAT1","pipe":"","alterations":" ","tags":["KLRG1 • B3GAT1"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-01-07"},{"id":"c41f6dcf-1a0e-427e-84b3-c66ecc85d44e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05998408","created_at":"2023-08-21T16:09:13.482Z","updated_at":"2024-07-02T16:35:06.081Z","phase":"Phase 1/2","brief_title":"JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure","source_id_and_acronym":"NCT05998408","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/20/2024","start_date":" 02/20/2024","primary_txt":" Primary completion: 06/03/2030","primary_completion_date":" 06/03/2030","study_txt":" Completion: 06/03/2032","study_completion_date":" 06/03/2032","last_update_posted":"2024-05-03"},{"id":"91b3d9ac-4a35-4c56-af84-44c4a37e09b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01976182","created_at":"2021-01-18T08:59:58.363Z","updated_at":"2024-07-02T16:35:19.346Z","phase":"Phase 2","brief_title":"Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia","source_id_and_acronym":"NCT01976182","lead_sponsor":"Rennes University Hospital","biomarkers":" CD8 • NCAM1 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • NCAM1 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • methotrexate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 166","initiation":"Initiation: 11/26/2013","start_date":" 11/26/2013","primary_txt":" Primary completion: 02/05/2024","primary_completion_date":" 02/05/2024","study_txt":" Completion: 05/26/2027","study_completion_date":" 05/26/2027","last_update_posted":"2024-02-14"},{"id":"eb372b62-ee59-4346-9e79-7fe21ffd6215","acronym":"NCI-2022-02385","url":"https://clinicaltrials.gov/study/NCT05592015","created_at":"2022-10-24T13:57:03.902Z","updated_at":"2024-07-02T16:35:21.586Z","phase":"Phase 2","brief_title":"Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia","source_id_and_acronym":"NCT05592015 - NCI-2022-02385","lead_sponsor":"John Reneau","biomarkers":" CD8 • STAT3 • B3GAT1","pipe":" | ","alterations":" STAT3 mutation","tags":["CD8 • STAT3 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-31"},{"id":"d5870014-be37-4a8f-b38f-acf430db9ed2","acronym":"TIBIOP-LMC","url":"https://clinicaltrials.gov/study/NCT04645706","created_at":"2021-01-19T20:39:33.885Z","updated_at":"2024-07-02T16:35:40.883Z","phase":"","brief_title":"Innate T Cells and TKI Discontinuation","source_id_and_acronym":"NCT04645706 - TIBIOP-LMC","lead_sponsor":"Poitiers University Hospital","biomarkers":" CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20","pipe":" | ","alterations":" CD8 expression • IFNG expression","tags":["CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-08-04"},{"id":"f8bfbabd-a095-4dce-9f97-609ef1a78c91","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225584","created_at":"2022-11-09T15:57:03.257Z","updated_at":"2024-07-02T16:35:41.087Z","phase":"Phase 1","brief_title":"Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors","source_id_and_acronym":"NCT05225584","lead_sponsor":"Kymera Therapeutics, Inc.","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KT-333"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/19/2022","start_date":" 05/19/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-08-03"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"6e4a9e4c-283b-45a8-92e3-5b41e4fbb313","acronym":"","url":"https://clinicaltrials.gov/study/NCT00345345","created_at":"2021-01-18T01:11:38.234Z","updated_at":"2024-07-02T16:36:11.133Z","phase":"Phase 2","brief_title":"Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia","source_id_and_acronym":"NCT00345345","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 10/17/2006","start_date":" 10/17/2006","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 10/27/2020","study_completion_date":" 10/27/2020","last_update_posted":"2022-05-03"},{"id":"f0fc99b5-d1de-433b-93c4-9263a9eb22b3","acronym":"BIOREN","url":"https://clinicaltrials.gov/study/NCT03628859","created_at":"2021-01-18T17:49:29.058Z","updated_at":"2024-07-02T16:36:15.363Z","phase":"","brief_title":"BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)","source_id_and_acronym":"NCT03628859 - BIOREN","lead_sponsor":"Centre Leon Berard","biomarkers":" IFNG • IL2RA • CD69 • NCAM1 • IL10 • ENTPD1 • B3GAT1 • ISG20 • KLRC1","pipe":"","alterations":" ","tags":["IFNG • IL2RA • CD69 • NCAM1 • IL10 • ENTPD1 • B3GAT1 • ISG20 • KLRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sunitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-03-15"},{"id":"5b3f5b6d-e741-425a-9b64-0beca6fd42d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03239392","created_at":"2021-01-18T16:00:27.423Z","updated_at":"2024-07-02T16:36:29.807Z","phase":"Phase 1/2","brief_title":"A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL","source_id_and_acronym":"NCT03239392","lead_sponsor":"Bioniz Therapeutics","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EQ101"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2021-05-25"},{"id":"50b98564-af98-43e8-826f-b2d64add86cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00076180","created_at":"2021-01-18T00:12:16.829Z","updated_at":"2024-07-02T16:37:03.924Z","phase":"Phase 1","brief_title":"Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia","source_id_and_acronym":"NCT00076180","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IL2 • B3GAT1","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • IL2 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hu-Mik-Beta-1"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 11/12/2010","primary_completion_date":" 11/12/2010","study_txt":" Completion: 01/09/2019","study_completion_date":" 01/09/2019","last_update_posted":"2019-01-11"},{"id":"8a095384-8795-49e2-975e-166b35eb9264","acronym":"","url":"https://clinicaltrials.gov/study/NCT00331591","created_at":"2021-01-18T01:08:40.620Z","updated_at":"2024-07-02T16:37:23.802Z","phase":"Phase 2","brief_title":"Response to Tipifarnib in Individuals With Large Granular Lymphocyte Leukemia","source_id_and_acronym":"NCT00331591","lead_sponsor":"Office of Rare Diseases (ORD)","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 05/01/2007","primary_completion_date":" 05/01/2007","study_txt":" Completion: 05/01/2007","study_completion_date":" 05/01/2007","last_update_posted":"2017-04-05"},{"id":"ed4f1efe-a30a-43c1-ae96-c92769958d75","acronym":"","url":"https://clinicaltrials.gov/study/NCT00031980","created_at":"2021-01-18T00:00:50.444Z","updated_at":"2024-07-02T16:37:30.820Z","phase":"Phase 2","brief_title":"Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer","source_id_and_acronym":"NCT00031980","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2002","start_date":" 03/01/2002","primary_txt":" Primary completion: 05/01/2005","primary_completion_date":" 05/01/2005","study_txt":" Completion: 05/01/2005","study_completion_date":" 05/01/2005","last_update_posted":"2016-07-06"}]